This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy CymaBay Therapeutics stock | $7.2

Own CymaBay Therapeutics stock in just a few minutes.


Fact checked

CymaBay Therapeutics, Inc is a biotechnology business based in the US. CymaBay Therapeutics shares (CBAY) are listed on the NASDAQ and all prices are listed in US Dollars. CymaBay Therapeutics employs 22 staff and has a market cap (total outstanding shares value) of USD$582.8 million.

How to buy shares in CymaBay Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for CymaBay Therapeutics. Find the stock by name or ticker symbol: CBAY. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until CymaBay Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$7.2, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of CymaBay Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of CymaBay Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

CymaBay Therapeutics share price

Use our graph to track the performance of CBAY stocks over time.

CymaBay Therapeutics shares at a glance

Information last updated 2020-10-20.
Latest market close USD$7.2
52-week range USD$1.21 - USD$8.71
50-day moving average USD$6.8773
200-day moving average USD$4.5041
Wall St. target price USD$12.73
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.375

Buy CymaBay Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy CymaBay Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

CymaBay Therapeutics price performance over time

Historical closes compared with the close of $7.2 from 2020-12-04

1 week (2020-11-25) -0.83%
1 month (2020-11-05) -15.29%
3 months (2020-09-04) 24.03%
6 months (2020-06-05) 88.48%
1 year (2019-12-05) 333.73%
2 years (2018-12-04) -17.71%
3 years (2017-12-05) -15.99%
5 years (2015-12-04) 400.00%

CymaBay Therapeutics financials

Gross profit TTM USD$-64,579,000
Return on assets TTM -22.78%
Return on equity TTM -39.59%
Profit margin 0%
Book value $2.404
Market capitalisation USD$582.8 million

TTM: trailing 12 months

Shorting CymaBay Therapeutics shares

There are currently 6.3 million CymaBay Therapeutics shares held short by investors – that's known as CymaBay Therapeutics's "short interest". This figure is 5.5% up from 6.0 million last month.

There are a few different ways that this level of interest in shorting CymaBay Therapeutics shares can be evaluated.

CymaBay Therapeutics's "short interest ratio" (SIR)

CymaBay Therapeutics's "short interest ratio" (SIR) is the quantity of CymaBay Therapeutics shares currently shorted divided by the average quantity of CymaBay Therapeutics shares traded daily (recently around 1.7 million). CymaBay Therapeutics's SIR currently stands at 3.76. In other words for every 100,000 CymaBay Therapeutics shares traded daily on the market, roughly 3760 shares are currently held short.

However CymaBay Therapeutics's short interest can also be evaluated against the total number of CymaBay Therapeutics shares, or, against the total number of tradable CymaBay Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CymaBay Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 CymaBay Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.0925% of the tradable shares (for every 100,000 tradable CymaBay Therapeutics shares, roughly 93 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against CymaBay Therapeutics.

Find out more about how you can short CymaBay Therapeutics stock.

CymaBay Therapeutics share dividends

We're not expecting CymaBay Therapeutics to pay a dividend over the next 12 months.

CymaBay Therapeutics share price volatility

Over the last 12 months, CymaBay Therapeutics's shares have ranged in value from as little as $1.21 up to $8.71. A popular way to gauge a stock's volatility is its "beta".

CBAY.US volatility(beta: 1.54)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CymaBay Therapeutics's is 1.5444. This would suggest that CymaBay Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

CymaBay Therapeutics overview

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis and sclerosing cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type 2 diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site